用于识别高危小肠克罗恩病的经验证风险分层工具
研究基于三个队列开发并验证了一个用于识别回肠型克罗恩病(CD)的简单风险预测工具。核心特征为排便习惯改变伴腹痛,结合白细胞计数、白蛋白和血小板计数异常,在训练队列中AUC为0.92(95%CI=0.89-0.92),并在两个验证队列中分别达到0.96(95%CI=0.95-0.98)和0.94(95%CI=0.92-0.96)。该工具旨在帮助初级保健医生更早识别潜在回肠CD并请求 urgent 专科评估。
要点
- 排便习惯改变伴腹痛联合白细胞计数、白蛋白和血小板计数异常是预测回肠CD的重要特征。
- 该风险预测算法在训练队列中AUC为0.92,在两个验证队列中分别为0.96和0.94。
- C反应蛋白与回肠CD独立相关,但在多变量模型中不显著。
核心结论
- 开发了一个基于客观指标和症状标准的网络风险分层工具,用于帮助初级保健医生更自信地为高危回肠CD患者请求紧急专科评估。
研究设计与样本
- 研究获取三个队列:队列1回顾性纳入2000至2010年间61例回肠CD患者和78例匹配对照;队列2前瞻性纳入42例回肠CD患者和57例对照;队列3纳入84例回肠CD患者和495例非CD对照。
- 收集临床症状和血清生物标志物,用于开发风险预测算法,算法在每个队列独立训练,并在后两个队列中测试。
主要发现
- 排便习惯改变伴腹痛联合白细胞计数、白蛋白和血小板计数异常是预测回肠CD的重要特征,AUC=0.92(95%CI=0.89-0.92)。
- 该算法在队列2中验证AUC=0.96(95%CI=0.95-0.98),在队列3中验证AUC=0.94(95%CI=0.92-0.96)。
- C反应蛋白与回肠CD独立相关,但在多变量模型中不显著。
关键数值与推荐
- 风险预测算法基于临床症状(排便习惯改变伴腹痛)和血清生物标志物(白细胞计数、白蛋白、血小板计数)构建。
临床怎么用
- 该网络风险分层工具可供初级保健医生使用,以识别回肠CD高危患者并更自信地请求紧急专科评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delays in Crohn's disease (CD) diagnosis are positively associated with ileal location and an increased risk of complications. AIM: To develop a simple risk assessment tool to enable primary care physicians to recognise potential ileal CD earlier, shortening the delay to specialist investigation METHODS: Three cohorts were acquired for this study. Cohort 1 included 61 patients retrospectively identified with ileal CD between 2000 and 2010 and 78 matched controls drawn from a cohort referred for investigation of abdominal symptoms. Cohort 2 included 42 individuals diagnosed with ileal CD and 57 controls identified prospectively. Cohort 3 included an additional 84 individuals with ileal CD and 495 without CD referred for colonoscopy. Clinical symptoms and serological biomarkers were acquired and used to develop a risk prediction algorithm. The algorithm was trained independently on each of the three cohorts and tested on the latter two cohorts. RESULTS: Altered bowel habit with abdominal pain combined with derangements in white cell count (WCC), albumin and platelet counts were important features in predicting ileal CD (AUC = 0.92, 95% CI = 0.89-0.92). This was validated in cohorts 2 (AUC = 0.96, 95% CI = 0.95-0.98) and 3 (AUC = 0.94, 95% CI = 0.92-0.96). C-reactive protein was independently associated with ileal CD but non-signficant in a multivariate model. CONCLUSION: A web-based risk stratification tool for ileal CD has been developed from objective and symptom-based criteria. This tool enables primary care physicians to more confidently request urgent specialist assessment for patients identified as at high risk for ileal CD.
引用
- Shen EX, Lord A, Doecke JD, et al. A validated risk stratification tool for detecting high-risk small bowel Crohn's disease. Aliment Pharmacol Ther. 2019. PMID: 31769537. doi:10.1111/apt.15550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。